Technologies available for licensing, investment, joint ventures and R&D contracts in Ukraine, Azerbaijan, Georgia, Moldova, Uzbekistan

Frontpage Slideshow (version 2.0.0) - Copyright © 2006-2008 by JoomlaWorks

Google Translate

Patenting Information

Tag Cloud

Free counters!

Home Azerbaijan Technologies 3-Methyl-5-Morpholinomethylisoxazole Showing Hypocoagulation, Antiaggregation and Fibrinolytic Activity

3-Methyl-5-Morpholinomethylisoxazole Showing Hypocoagulation, Antiaggregation and Fibrinolytic Activity


It is developed the regioselective method of preparation of 3-methyl-5-morpholinemethylisoxazole by interaction of 4,5-dichlor-3-penten-2-one with morpholine with the subsequent washing of intermediate product. The forming intermediate product after washing by diluted aqueous solution of soda is treated by hydroxylamine.

Innovative Aspect and Main Advantages

Novelty is the regioselective direction of reaction to the way of formation of 3-methyl-5-morpholinomethylisoxazole. Synthesis of indicated compound from intermediate 3,4- (bis)morpholino-3-penten-2-one containing one reaction center (C=O) for nucleophilic attack with hydroxylamine favors proceeding of reaction regioselectively. An introduction of 3- methyl-5-morpholinomethylisoxazole into rabbit intravenously in doses 100mg/kg in a day in 2 times increases hypocoagulant, in 1,5 times fibrinolytic and in 2 times antiaggregant activity in comparison with heparin, fibrinolysin and sodium salicylate, respectively. It is referred to non toxic compounds LD50=1039 mg/kg (750-1625) mg/kg.

Areas of Application

It can be applied in medicine as hypocoagulation, antiaggregation and fibrinolytic drugs.

Fig. 1 3-Methyl-5-morpholinomethylizoxazole.

Stage of Development

Laboratory tested on rabbits. Inv. Certificate USSR is received.

Contact Details

Institute of Polymer Materials
Contact persons: Gadzhili R.A.
Address: 124, S.Vurgun St. AZ5004, Sumgait, Azerbaijan
Tel: (+994 55) 706 1613; (+994 18) 644 6645; (+994 18) 642 2124
Fax: (+994 18) 642 0400
E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Add comment

Security code